945744-14-9

Basic information

• Product Name: di-tert-butyl 4-benzyloxycarbonylamino-4-[2-(tert-butoxycarbonyl)ethyl]-heptanedioate
• Synonyms: di-tert-butyl 4-benzyloxycarbonylamino-4-[2-(tert-butoxycarbonyl)ethyl]-heptanedioate
• CAS NO: 945744-14-9
• Molecular Weight: 381.383
• Mol File: 945744-14-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: di-tert-butyl 4-benzyloxycarbonylamino-4-[2-(tert-butoxycarbonyl)ethyl]-heptanedioate(CAS DataBase Reference)
• NIST Chemistry Reference: di-tert-butyl 4-benzyloxycarbonylamino-4-[2-(tert-butoxycarbonyl)ethyl]-heptanedioate(945744-14-9)
• EPA Substance Registry System: di-tert-butyl 4-benzyloxycarbonylamino-4-[2-(tert-butoxycarbonyl)ethyl]-heptanedioate(945744-14-9)

Safety Data

• Hazardous Substances Data: 945744-14-9(Hazardous Substances Data)

Upstream product

• 136586-99-7 4-amino-4-(2-tert-butoxycarbonylethyl)heptanedioic acid di-tertbutyl ester 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1326757-09-8 C₃₄H₄₄N₄O₉ 
• 1326757-08-7 C₄₂H₅₀N₄O₁₁ 

Relevant articles and documents

Sugar balls: Synthesis and supramolecular assembly of [60]fullerene glycoconjugates

The synthesis and characterization of fully deprotected C60 glycoconjugates 4 and 17 is reported. Bis(α-D-mannopyranosyl)malonamide 4 was obtained by using nucleophilic cyclopropanation chemistry, which in general is a very versatile method for

METHODS FOR TREATING HEPATITIS B INFECTIONS

Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient's genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations.

TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS

The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).